APP antisense oligonucleotides reduce amyloid-β aggregation and rescue endolysosomal dysfunction in Alzheimer’s disease
Open Access
- 25 March 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 147 (7) , 2325-2333
Abstract
APP gene dosage is strongly associated with Alzheimer’s disease (AD) pathogenesis. Genomic duplication of the APP locus leads to autosomal dominant early-onset AD. Individuals with Down syndrome (trisomy of chromosome 21) harbour three copies of the APP gene and invariably develop progressive AD with highly characteristic neuropathological features. Restoring expression of APP to the equivalent of that of two gene copies, or lower, is a rational therapeutic strategy, as it would restore physiological levels of neuronal APP protein without the potentially deleterious consequences of inadvertently inducing loss of APP function. Here we find that antisense oligonucleotides (ASOs) targeting APP are an effective approach to reduce APP protein levels and rescue endolysosome and autophagy dysfunction in APP duplication and Trisomy 21 human induced pluripotent stem cell (hiPSC)-derived cortical neurons. Importantly, using ultrasensitive single-aggregate imaging techniques, we show that APP targeting ASOs significantly reduce both intracellular and extracellular amyloid-β-containing aggregates. Our results highlight the potential of APP ASOs as a therapeutic approach for forms of AD caused by duplication of the APP gene, including monogenic AD and AD related to Down syndrome.Keywords
This publication has 29 references indexed in Scilit:
- Antisense oligonucleotides for Alzheimer's disease therapy: from the mRNA to miRNA paradigmEBioMedicine, 2021
- SORL1 deficiency in human excitatory neurons causes APP-dependent defects in the endolysosome-autophagy networkCell Reports, 2021
- Variable Outcomes in Neural Differentiation of Human PSCs Arise from Intrinsic Differences in Developmental Signaling PathwaysCell Reports, 2020
- Leveraging preclinical models for the development of Alzheimer disease therapeuticsNature Reviews Drug Discovery, 2020
- A Large Panel of Isogenic APP and PSEN1 Mutant Human iPSC Neurons Reveals Shared Endosomal Abnormalities Mediated by APP β-CTFs, Not AβNeuron, 2019
- Altered γ-Secretase Processing of APP Disrupts Lysosome and Autophagosome Function in Monogenic Alzheimer’s DiseaseCell Reports, 2018
- Targeting Amyloid-β Precursor Protein, APP, Splicing with Antisense Oligonucleotides Reduces Toxic Amyloid-β ProductionMolecular Therapy, 2018
- Dysfunction of autophagy and endosomal-lysosomal pathways: Roles in pathogenesis of Down syndrome and Alzheimer's DiseaseFree Radical Biology and Medicine, 2018
- APP Metabolism Regulates Tau Proteostasis in Human Cerebral Cortex NeuronsCell Reports, 2015
- A mutation in APP protects against Alzheimer’s disease and age-related cognitive declineNature, 2012